These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30901006)

  • 1. Size-controlled synthesis of polymerized DNA nanoparticles for targeted anticancer drug delivery.
    Nam K; Kim T; Kim YM; Yang K; Choe D; Mensah LB; Choi KY; Roh YH
    Chem Commun (Camb); 2019 Apr; 55(34):4905-4908. PubMed ID: 30901006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
    Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinspired Core-Shell Nanoparticles for Hydrophobic Drug Delivery.
    Yang G; Liu Y; Wang H; Wilson R; Hui Y; Yu L; Wibowo D; Zhang C; Whittaker AK; Middelberg APJ; Zhao CX
    Angew Chem Int Ed Engl; 2019 Oct; 58(40):14357-14364. PubMed ID: 31364258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
    Baghbani F; Moztarzadeh F
    Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma.
    Tomasina J; Poulain L; Abeilard E; Giffard F; Brotin E; Carduner L; Carreiras F; Gauduchon P; Rault S; Malzert-Fréon A
    Int J Pharm; 2013 Dec; 458(1):197-207. PubMed ID: 24084450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-functionalized albumin-based nanoparticles for targeted drug delivery.
    Xu L; He XY; Liu BY; Xu C; Ai SL; Zhuo RX; Cheng SX
    Colloids Surf B Biointerfaces; 2018 Nov; 171():24-30. PubMed ID: 30005287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
    She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
    Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles.
    Zhang LK; Hou SX; Zhang JQ; Hu WJ; Wang CY
    Arch Pharm Res; 2010 Aug; 33(8):1193-8. PubMed ID: 20803122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.
    Noorani L; Stenzel M; Liang R; Pourgholami MH; Morris DL
    J Nanobiotechnology; 2015 Mar; 13():25. PubMed ID: 25890381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biocompatible APTES-PEG modified magnetite nanoparticles: effective carriers of antineoplastic agents to ovarian cancer.
    Javid A; Ahmadian S; Saboury AA; Kalantar SM; Rezaei-Zarchi S; Shahzad S
    Appl Biochem Biotechnol; 2014 May; 173(1):36-54. PubMed ID: 24615524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
    Stewart J; George A; Banerjee S
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics.
    Toubhans B; Gazze SA; Bissardon C; Bohic S; Gourlan AT; Gonzalez D; Charlet L; Conlan RS; Francis LW
    Nanomedicine; 2020 Oct; 29():102258. PubMed ID: 32615338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
    Gyparaki MT; Papavassiliou AG
    Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
    [No Abstract]   [Full Text] [Related]  

  • 15. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.
    Moioli M; Barra F; Maramai M; Valenzano Menada M; Vellone VG; Costantini S; Ferrero S
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1025-1029. PubMed ID: 31726889
    [No Abstract]   [Full Text] [Related]  

  • 16. A novel size-tunable nanocarrier system for targeted anticancer drug delivery.
    Li Y; Xiao K; Luo J; Lee J; Pan S; Lam KS
    J Control Release; 2010 Jun; 144(3):314-23. PubMed ID: 20211210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced drug loading on magnetic nanoparticles by layer-by-layer assembly using drug conjugates: blood compatibility evaluation and targeted drug delivery in cancer cells.
    Manju S; Sreenivasan K
    Langmuir; 2011 Dec; 27(23):14489-96. PubMed ID: 21988497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
    Lale SV; R G A; Aravind A; Kumar DS; Koul V
    Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review.
    Kamath PR; Sunil D
    Mini Rev Med Chem; 2017; 17(15):1457-1487. PubMed ID: 28245780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery.
    Lee JY; Termsarasab U; Park JH; Lee SY; Ko SH; Shim JS; Chung SJ; Cho HJ; Kim DD
    J Control Release; 2016 Aug; 236():38-46. PubMed ID: 27320169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.